EMD Serono and EMD Group (EMD Millipore (Massachusetts)) Expand Collaboration to Include Unlimited Access to OmniRat® Human Antibody Platform
10/28/2013 10:43:50 AM
PALO ALTO, Calif.--(BUSINESS WIRE)--EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, and Open Monoclonal Technology, Inc. (OMT), a leader in the genetic engineering of animals for development of human therapeutic antibodies, today announced expansion of their collaboration agreement from June 2012. Under the terms of the new agreement, EMD Serono will make an upfront payment to secure unlimited access to the OmniRat platform as well as success-based development milestones and royalties. Further details of the contract are not being disclosed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by